Centene CNC
Centene is a managed healthcare insurer in the United States offering Medicaid, Medicare, and marketplace plans, acting as an intermediary between state governments and beneficiaries. Centene trades at an attractive valuation (forward P/E 11.56, FCF yield 31.57%) and strong momentum (85.74% over 12 months), but its return on equity is negative (ROE -20.36%) and operating margin is low (3.76%), reflecting the challenges of the Medicaid business.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Centene is a managed healthcare insurer in the United States offering Medicaid, Medicare, and marketplace plans, acting as an intermediary between state governments and beneficiaries. Centene trades at an attractive valuation (forward P/E 11.56, FCF yield 31.57%) and strong momentum (85.74% over 12 months), but its return on equity is negative (ROE -20.36%) and operating margin is low (3.76%), reflecting the challenges of the Medicaid business.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.3 |
| Quality / Moat | 5.0 |
| Valuation | 5.0 |
| Growth | 5.5 |
| Dividend | 1.5 |
| Momentum | 9.7 |
| Risk & Context | 5.2 |
OVERALL SCORE: 5.4/10
Context and risks
Moderate regulatory risk in the U.S. for managed care insurers, with pressure on Medicaid rates and industry review. Centene's position as a government intermediary exposes it to changes in state funding.
News considered in the analysis
- 1 Cash-Heavy Stock to Own for Decades and 2 We Turn Down — Listículo genérico sin información específica sobre Centene.
- What Does Centene (CNC) Gain From Its Credentialing Push And Emergency Response? — Iniciativas operativas que pueden mejorar la eficiencia y la calidad del servicio, pero sin impacto financiero cuantificado.
- Best Growth Stocks to Buy for September 24th — Inclusión en una lista de crecimiento de Zacks, señal positiva de analistas, pero sin noticia fundamental nueva.
- Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know — Noticia sobre otras empresas del sector salud, sin impacto directo en Centene.
- Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know — Movimientos de otras compañías de salud, sin relevancia para Centene.
Verdict: Hold, given the balance between cheap valuation and regulatory and margin risks; monitor Medicaid rate developments.
Main risk: Dependence on government funding (Medicaid) and regulatory risk in the U.S., which could compress margins or affect beneficiary eligibility.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →